Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery
Sponsor : GSK
Deal Size : $7,200.0 million
Deal Type : Collaboration
GSK becomes Flagship's latest partner in $7B biobucks respiratory, immunology pact
Details : The Flagship collaborates with GSK to discover and develop a portfolio of future transformational medicines and vaccines for the treatment of respiratory and immunology diseases.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : $150.0 million
July 29, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Sponsor : GSK
Deal Size : $7,200.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery
Sponsor : The Jikei University
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Sponsor : The Jikei University
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery
Sponsor : Chiesi Group
Deal Size : $214.0 million
Deal Type : Collaboration
Details : Under the terms of the collaboration, Affibody and Chiesi Group will collaborate closely to progress up to three programs based on Affibody® molecules against undisclosed targets for respiratory diseases.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 07, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Sponsor : Chiesi Group
Deal Size : $214.0 million
Deal Type : Collaboration
Lead Product(s) : RBO-0618
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery
Sponsor : California Institute for Regenerative Medicine
Deal Size : $1.4 million
Deal Type : Funding
Details : The funding will support research and development of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis (IPF), RBO-0618, targeting senescent lung stem cells.
Brand Name : RBO-0618
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 06, 2023
Lead Product(s) : RBO-0618
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Sponsor : California Institute for Regenerative Medicine
Deal Size : $1.4 million
Deal Type : Funding
Lead Product(s) : mRNA Therapeutics
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery
Sponsor : Chiesi Group
Deal Size : $425.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Moderna will lead discovery efforts, leveraging its leading mRNA technology and delivery platforms along with Chiesi’s expertise in the field of PAH biology.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $25.0 million
September 16, 2020
Lead Product(s) : mRNA Therapeutics
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Sponsor : Chiesi Group
Deal Size : $425.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Discovery
Sponsor : Bayer AG
Deal Size : $1,030.0 million
Deal Type : Collaboration
Details : The partnership will leverage Recursion’s purpose-built-AI-guided drug discovery platform and Bayer’s small molecule compound library and deep scientific expertise to discover and develop new treatments for fibrotic diseases of the lung, kidney, hear...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $30.0 million
September 09, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Discovery
Sponsor : Bayer AG
Deal Size : $1,030.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?